COVID-19 vaccines are safe and effective.
Millions of people in the United States have received COVID-19
vaccines under the most intense safety monitoring in U.S. history.
CDC recommends everyone ages 5 years and older get vaccinated as soon
as possible to help protect against COVID-19 and the related,
potentially severe complications that can occur.
CDC, the U.S. Food and Drug Administration (FDA), and other federal
agencies are monitoring the safety of COVID-19 vaccines.
Adverse events described on this page have been reported to the
Vaccine Adverse Event Reporting System (VAERS)external icon.
VAERS accepts reports of any adverse event following any vaccination.
Reports of adverse events to VAERS following vaccination, including
deaths, do not necessarily mean that a vaccine caused a health
Serious adverse events after COVID-19 vaccination are rare but may
For public awareness and in the interest of transparency, CDC is
providing timely updates on the following serious adverse events of
Anaphylaxis, a severe type of allergic reaction, following
administration of COVID-19 vaccination is rare and has occurred in
approximately 2 to 5 people per million vaccinated in the United
States. Anaphylaxis can occur after any kind of vaccination. If it
happens, healthcare providers can effectively and immediately treat
the reaction. Learn more about COVID-19 vaccines and allergic
reactions, including anaphylaxis.
Thrombosis with thrombocytopenia syndrome (TTS) occurring after
Johnson & Johnson’s Janssen (J&J/Janssen) COVID-19 vaccination is
rare. As of November 10, 2021, more than 16 million doses of the
J&J/Janssen COVID-19 vaccine have been given in the United States. CDC
and FDA have identified 50 confirmed reports of people who got the
J&J/Janssen COVID-19 vaccine and later developed TTS, including 5
confirmed reports of death. Women ages 18-49, especially, should be
aware of the rare but increased risk of this adverse event. There are
other COVID-19 vaccine options available for which this risk has not
been seen. Learn more about J&J/Janssen COVID-19 vaccine and TTS.
To date, two confirmed cases of TTS following mRNA COVID-19
vaccination (Moderna) have been reported to VAERS after more than 418
million doses of mRNA COVID-19 vaccines administered in the United
States. Based on available data, there is not an increased risk for
TTS after mRNA COVID-19 vaccination.
CDC and FDA are monitoring reports of Guillain-Barré Syndrome (GBS) in
people who have received the J&J/Janssen COVID-19 vaccine. GBS is a
rare disorder where the body’s immune system damages nerve cells,
causing muscle weakness and sometimes paralysis. Most people fully
recover from GBS, but some have permanent nerve damage. After more
than 16 million J&J/Janssen COVID-19 vaccine doses administered, there
have been around 258 preliminary reports of GBS identified in VAERS as
of November 10, 2021. These cases have largely been reported about 2
weeks after vaccination and mostly in men, many ages 50 years and
older. CDC will continue to monitor for and evaluate reports of GBS
occurring after COVID-19 vaccination and will share more information
as it becomes available.
Myocarditis and pericarditis occurring after COVID-19 vaccination are
rare. As of November 10, 2021, VAERS has received 1,793 reports of
myocarditis or pericarditis among people ages 12–29 years who received
COVID-19 vaccines. Most cases have been reported after mRNA COVID-19
vaccination (Pfizer-BioNTech or Moderna), particularly in male
adolescents and young adults after the second dose. Through follow-up,
including medical record reviews, CDC and FDA have confirmed 1,049
reports of myocarditis or pericarditis. Learn more about myocarditis
and pericarditis after mRNA COVID-19 vaccination.
Reports of death after COVID-19 vaccination are rare. More than 442
million doses of COVID-19 vaccines were administered in the United
States from December 14, 2020, through November 15, 2021. During this
time, VAERS received 9,810 reports of death (0.0022%) among people who
received a COVID-19 vaccine. FDA requires healthcare providers to
report any death after COVID-19 vaccination to VAERS, even if it’s
unclear whether the vaccine was the cause. Reports of adverse events
to VAERS following vaccination, including deaths, do not necessarily
mean that a vaccine caused a health problem. A review of available
clinical information, including death certificates, autopsy, and
medical records has not established a causal link to COVID-19
vaccines. However, recent reports indicate a plausible causal
relationship between the J&J/Janssen COVID-19 vaccine and TTS, a rare
and serious adverse event that causes blood clots with low platelets,
which has caused 5 deaths pdf icon[1,438 KB, 33 pages].
This amounts to FIVE deaths proven to be caused by the J&J vaccine and
258 cases of GBS MAY be attrutable to the J&J vaccine.
There were 1049 cases of Myocarditis and pericarditis among people 12
to 29 who were vaccinated. (and no deaths!!) (out of roughly 9 million
vaccinated in that age group)
How many cases in the unvaccinated population???? The average over
the last 10 or 15 years is reportedly at least 2 per 100000. - so
about 180 of those cases are statistically unlikely to have been
caused by the vaccine. (so realistically? 850 cases possibly due to
Also, significantly, up to 7 percent of Covid deaths showed evidence
of myocardial or pericardial tissue involvement consistent with
Myocarditis or pericarditis,
At 235 deaths per 100000, with 7% of them suspected of having myo or
pericarditis, that is 16.5 per 100000 - so with 700000 covid deaths
that is 116 Covid deaths due to myo and pericarditis